The invasive-disease-free survival analysis demonstrated enhanced TNBC-specific survival rate in patients with higher tumor expression of RIPK1 (Fig. 2E; hazard ratio, 0.31; p = 0.065). The gene discussed is RIPK1; the disease is neoplasm.